WallStreetZenWallStreetZen

NASDAQ: ACST
Acasti Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ACST

Based on 1 analyst offering 12 month price targets for Acasti Pharma Inc.
Min Forecast
$6.00+104.85%
Avg Forecast
$6.00+104.85%
Max Forecast
$6.00+104.85%

Should I buy or sell ACST stock?

Based on 1 analyst offering ratings for Acasti Pharma Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ACST stock forecasts and price targets.

ACST stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-07

1 of 1

Forecast return on equity

Is ACST forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is ACST forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ACST revenue forecast

What is ACST's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$1.4M
Avg 2 year Forecast
$39.0M
Avg 3 year Forecast
$71.5M

ACST vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACST$2.93$6.00+104.85%Buy
SRZN$8.61N/AN/A
IGC$0.43N/AN/A
PTN$1.72$70.00+3,969.77%Buy
ENLV$1.45$7.00+382.76%Buy
View Top Biotech Stocks

Acasti Pharma Stock Forecast FAQ

Is Acasti Pharma Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ACST) stock is to Buy ACST stock.

Out of 1 analyst, 0 (0%) are recommending ACST as a Strong Buy, 1 (100%) are recommending ACST as a Buy, 0 (0%) are recommending ACST as a Hold, 0 (0%) are recommending ACST as a Sell, and 0 (0%) are recommending ACST as a Strong Sell.

If you're new to stock investing, here's how to buy Acasti Pharma stock.

What is ACST's revenue growth forecast for 2026-2028?

(NASDAQ: ACST) Acasti Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Acasti Pharma's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ACST's revenue for 2026 to be $13,535,142, with the lowest ACST revenue forecast at $13,535,142, and the highest ACST revenue forecast at $13,535,142. On average, 1 Wall Street analysts forecast ACST's revenue for 2027 to be $366,858,738, with the lowest ACST revenue forecast at $366,858,738, and the highest ACST revenue forecast at $366,858,738.

In 2028, ACST is forecast to generate $671,963,392 in revenue, with the lowest revenue forecast at $671,963,392 and the highest revenue forecast at $671,963,392.

What is ACST's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: ACST) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is ACST's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ACST price target, the average ACST price target is $6.00, with the highest ACST stock price forecast at $6.00 and the lowest ACST stock price forecast at $6.00.

The Wall Street analyst predicted that Acasti Pharma's share price could reach $6.00 by Feb 7, 2025. The average Acasti Pharma stock price prediction forecasts a potential upside of 104.85% from the current ACST share price of $2.93.

What is ACST's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: ACST) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.